PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11843366

Dosimetric models for thorium and practical problems in assessing intakes.

N Stradling·A Phipps·A Hodgson
View original source ↗Export metadata ↓

Abstract

An overview is given of the models recommended by the International Commission on Radiological Protection (ICRP) for assessing intakes and doses, and summarises biokinetic data obtained after the deposition of different chemical compounds of thorium in the rat lung. The results emphasise the importance of using material-specific data rather than default reference values for absorption into blood. The limitations of external monitoring of the chest or urine analysis are discussed, and comments made on alternative strategies for radiological protection of the worker.

Explore related subjects

Administration, InhalationAnimalsHumansMetabolic Clearance RateModels, BiologicalOccupational ExposureRadiation DosageRadiation ProtectionRadiometryRatsThoriumTissue DistributionJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Stradling, A Phipps, A Hodgson. 2001. Dosimetric models for thorium and practical problems in assessing intakes.. https://doi.org/10.1093/oxfordjournals.rpd.a006663

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗